Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of price leadership in the pharmaceutical sector, particularly in the context of rising raw material costs due to geopolitical tensions and supply chain disruptions [2] - The report highlights the approval of China's first invasive brain-machine interface, marking a significant milestone in medical technology and potential market opportunities [5] - The report notes a strong trend in China's innovative drug exports, with a significant increase in licensing deals and collaborations, indicating robust growth in the sector [6] Summary by Sections Supply Chain and Pricing Dynamics - The report discusses the impact of macroeconomic changes on supply chains, particularly the price increases in upstream chemical products affecting pharmaceutical raw materials [2] - It mentions that 90% of monitored products saw price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] - Specific raw materials like Vitamin E and methionine have seen price increases of 40.54% and 84.66% respectively since the start of the year [2] Market Trends and Innovations - The report details the rising prices of disposable gloves due to increased costs of upstream materials, with notable price hikes in butadiene and acrylonitrile [3] - It highlights the competitive landscape for disposable gloves, noting that leading companies are leveraging their cost advantages to implement price increases [3] - The report also discusses the potential for domestic medical products to benefit from export controls on dual-use items, enhancing China's competitive edge [4] Regulatory Developments and Market Opportunities - The approval of the brain-machine interface by the National Medical Products Administration is a significant development, with a large potential patient base in China [5] - The report outlines the introduction of new pricing guidelines for invasive brain-machine interfaces, which could facilitate market entry and reimbursement [5] Investment Recommendations - The report recommends focusing on raw material producers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Yingke Medical and Blue Sail Medical in the disposable glove sector [8] - It suggests monitoring companies benefiting from resource management policies, such as Aidi Te, and those involved in the invasive brain-machine interface market, like Meihua Medical [8] - The report also emphasizes the growth potential in the small nucleic acid drug sector, recommending companies like Yuyuan Pharmaceutical and Sunshine Nuohe [8] Company Performance and Forecasts - The report provides earnings forecasts for key companies, indicating a positive outlook for several firms in the pharmaceutical sector, with specific EPS and PE ratios highlighted for investment consideration [9]

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The National Development and Reform Commission has issued the "14th Five-Year Plan for the Development of the Bioeconomy," indicating a trillion-yuan market potential in the bioeconomy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a wave of technological advancements and increased investment, with nearly 100 companies completing new financing rounds since 2025 [33] Company Developments - Huaxi Biological's pilot platform has already undertaken over 30 biological manufacturing projects, facilitating the transition from laboratory-scale to commercial-scale production [10] - The report mentions that Lif Biological's PEF (polyethylene furanoate) has received approval for food contact use, marking a significant step for bio-based materials in the food packaging sector [24] - Watson Biological has announced a 450 million yuan investment to establish a fund focused on synthetic biology, with a target size of 1 billion yuan [25] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with companies like Rhein Biological and EcoviaBio completing multiple rounds of financing to expand their production capabilities [33][34] - Rhein Biological is focusing on two main development directions: enhancing its core business and providing industrialization services for external synthetic biology products [34]

Investment Rating - The industry investment rating is "Buy" [1] Core Insights - The report highlights the rapid growth of synthetic biology, with a significant increase in the number of synthetic biology companies in Beijing's Changping District, which has surged nearly 70% compared to the same period last year, reaching a total of 146 companies [9] - The establishment of the world's largest pilot transformation platform by Huaxi Biological in Tianjin, which has a total investment of several billion yuan and spans 40,000 square meters, is a key development in the industry [10] - The "14th Five-Year Plan" for the development of the bio-economy has been issued by the National Development and Reform Commission, indicating a trillion-yuan market potential in the bio-economy sector [4] Market Dynamics - The Huaxi Synthetic Biology Index decreased by 0.49% to 1271.82 during the week of February 24-27, 2026, underperforming compared to the Shanghai Composite Index, which rose by 1.98% [5] - The report notes that the synthetic biology sector is experiencing a biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, and food security [4] Company Developments - The report mentions that Watson Bio has established a 450 million yuan industry fund focused on synthetic biology, with a target size of 1 billion yuan [25] - Jin Dan Technology announced an additional investment of approximately 148 million yuan in its 75,000-ton annual production project for polylactic acid, bringing the total investment to 1.03 billion yuan [26] - The report also highlights the successful commercialization of products such as mannitol and alonose by companies like Weiyuan Synthetic [9] Industry Financing - The report indicates that financing in the synthetic biology sector is accelerating, with nearly 100 companies completing new financing rounds since 2025 [33] - EcoviaBio completed a Series B financing round to expand its production capacity for gamma-polyglutamic acid, a biodegradable material [34] - Verley, a precision fermentation company, successfully completed a $38 million Series A financing, marking a significant step towards commercializing precision fermentation [34]

关于公司产品中选国家集采药品接续采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002019 证券简称：亿帆医药 公告编号：2026-013 亿帆医药股份有限公司 亿帆医药股份有限公司（以下简称"公司"）全资子公司宿州亿帆药业有限 公司、辽宁亿帆药业有限公司参加了国家组织集采第 1-8 批协议期满品种接续采 购的申报，根据国家组织集采药品协议期满品种接续采购办公室于 2026 年 2 月 27 日 发 布 的 《 关 于 公 布 国 家 组 织 集 采 药 品 协 议 期 满 品 种 接 续 采 购 （LC-YPJX-2026-1）中选结果的通知》显示，公司部分产品中选本次接续采购， 现将相关情况公告如下： | 药品名称 | 适应症 | 采购周期 | | --- | --- | --- | | 拉考沙胺片 | 适用于 岁及以上癫痫患者部分性发作的单药治疗和联合治疗。 4 | | | | 适用于末次胸痛发作 小时之内且伴有 改变和/或心肌酶升 12 ECG | 自中选结果执行之日 | | | 高的非 ST 段抬高型急性冠脉综合征（NSTE- ...

Core Viewpoint - Yifan Pharmaceutical has made progress in its long-term strategy of "integration, innovation, and internationalization" since 2016, particularly in globalizing its pharmaceutical products and enhancing its sales and risk resistance capabilities [2] Group 1: Company Achievements - The company has seen a year-on-year increase in sales of its proprietary pharmaceutical products since 2020, indicating a positive trend in revenue growth [2] - In the past two years, the revenue from the company's innovative drug products has continued to expand, which is expected to significantly improve the quality of future profits [2]

Core Viewpoint - Yifan Pharmaceutical emphasizes its commitment to strict compliance with accounting standards and transparency in financial reporting, ensuring accurate information disclosure to protect investor rights [2]. Group 1: Accounting Practices - The company adheres to the "Enterprise Accounting Standards" and other legal regulations in its accounting practices [2]. - Yifan Pharmaceutical maintains a prudent and compliant approach to financial reporting [2]. - The impairment provisions are based on objective facts related to the market, industry, and products, following professional assessments [2]. Group 2: Internal Control and Risk Management - The company is committed to continuously improving internal controls and enhancing risk assessment processes [2]. - Yifan Pharmaceutical aims to increase the transparency of its accounting practices [2]. - The company prioritizes the protection of investor rights through its financial practices [2].

Core Viewpoint - On February 26, brokerages provided target prices for listed companies, with notable increases for Hongsoft Technology, China Railway, and Yifan Pharmaceutical, showing target price increases of 47.71%, 34.96%, and 32.82% respectively, across the IT services, infrastructure, and chemical pharmaceutical industries [1][2]. Group 1: Target Price Increases - Hongsoft Technology received a target price increase of 47.71%, with a new target price of 71.27 CNY [3]. - China Railway's target price increased by 34.96%, with a new target price of 8.30 CNY [3]. - Yifan Pharmaceutical's target price rose by 32.82%, with a new target price of 17.40 CNY [3]. Group 2: Brokerage Recommendations - A total of 27 listed companies received brokerage recommendations on February 26, with China Railway, Bohui Paper, and Zhujiang Beer each receiving one recommendation [2]. - Bohui Paper's rating was upgraded from "Range Trading" to "Buy" by Guotai Junan Securities [5]. Group 3: Rating Adjustments - Two companies had their ratings downgraded: Baolong Technology from "Buy" to "Hold" by Tianfeng Securities, and Haiguang Information from "Buy" to "Range Trading" by Guotai Junan Securities [6][8]. - The companies involved in the downgrades were Baolong Technology and Haiguang Information [8]. Group 4: First Coverage - Six companies received first coverage on February 26, including Matrix Co. and Anfu Technology, both rated "Outperform" by Guotai Junan Securities [10]. - Other companies receiving first coverage included Aorite with a "Buy" rating from Zhongyou Securities, Delijia with a "Buy" rating from Dongwu Securities, and Hanguo Group with an "Increase" rating from Dongguan Securities [10].

Group 1 - The core viewpoint of the article highlights the target price increases for certain companies, with notable gains for Hongsoft Technology, China Railway, and Yifan Pharmaceutical, showing increases of 47.71%, 34.96%, and 32.82% respectively, across the IT services, infrastructure, and chemical pharmaceuticals sectors [1] Group 2 - On February 26, brokerages lowered ratings for two listed companies, with Tianfeng Securities downgrading Baolong Technology from "Buy" to "Hold" and Qunyi Securities (Hong Kong) downgrading Haiguang Information from "Buy" to "Range Trading" [1]

Group 1 - The company and its subsidiaries, Suzhou Yifan Pharmaceutical Co., Ltd. and Beijing Yiyi Biopharmaceutical Co., Ltd., have received the "High-tech Enterprise Certificate" from relevant authorities, confirming their status as high-tech enterprises [1] - The recognition of high-tech enterprise status allows both subsidiaries to enjoy a preferential corporate income tax rate of 15% for three consecutive years from 2025 to 2027, following the expiration of their previous certificates [1] - The company has already filed tax returns for 2025 at the 15% rate, indicating that the new recognition will not impact the financial data for 2025 but is expected to have a positive effect on the company's operating performance in subsequent years [1]